FXR has emerged as a potential therapeutic target for a variety of diseases, including primary biliary cholangitis (PBC)32,33, non-alcoholic fatty liver disease (NAFLD)34, and acute kidney injury.35 Therefore, we investigated the potential therapeutic effects of FXR pharmacological activation on osteoporosis. This evidence concerns the gene NR1H4 and acute kidney injury.